Top Markets
Coin of the day
Hancock Jaffe Laboratories Hancock Jaffe Laboratories

Hancock Jaffe Laboratories

HJLI
Rang in aandelen #35033
Hancock Jaffe Laboratories, Inc. is a medical device company in its... Hancock Jaffe Laboratories, Inc. is a medical device company in its developmental stage, specializing in creating advanced tissue-based and biologic solutions. These innovations are engineered to either sustain or significantly enhance the lives of patients afflicted with cardiovascular, peripheral arterial, and venous diseases, as well as end-stage renal disease (ESRD). The firm, headquartered in Irvine, California, maintains a dedicated team of nine full-time employees. Among its key initiatives, the company is actively developing implantable bioprosthetic devices for cardiovascular applications. This includes the Bioprosthetic Heart Valve (BHV), a swine-derived heart valve designed to mimic the function of a native heart valve and provide superior performance compared to current prosthetic options. Furthermore, the company is developing a Venous Valve, another bioprosthetic device sourced from pig tissue. This valve is specifically designed for individuals suffering from chronic venous insufficiency (CVI) in the lower limbs, a condition frequently resulting from damage to leg vein valves after the formation of deep venous blood clots.
Aandeelprijs
$10.38
Laatst gesynchroniseerd: 2021-09-30
Marktkapitalisatie
$4.55M
Verandering (1 dag)
-1.98%
Verandering (1 jaar)
0.00%
Land
US
Handel Hancock Jaffe Laboratories (HJLI)

Categorie

Aandelsplitsingen voor Hancock Jaffe Laboratories (HJLI)
Het aandeel Hancock Jaffe Laboratories (symbool: HJLI) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 16, 2026.
Eén aandeel HJLI dat vóór Aug 16, 2026 werd gekocht, staat nu gelijk aan 0 aandelen HJLI.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
9 x285
US
9 x162
US
7 x127
IE
2 x4
US
3 x12
US